Differential localization of type I and type II benzodiazepine binding sites in substantia nigra

Mathew M S Lo, Debra L. Niehoff, Michael J. Kuhar, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

A number of studies have suggested the existence of multiple benzodiazepine binding sites in the brain1-20. We have recently reported the physical separation of two apparent benzodiazepine binding site subtypes 21, the pharmacological properties, and distribution in tissue sections of which correspond to the putative type I and type II sites 20,22. Benzodiazepine and γ-aminobutyric acid (GABA) receptors have been shown to interact23, and lesions of the GABAergic striatonigral pathway, which lead to GABA supersensitivity24,25, both increase the numbers of GABA binding sites24,26 and enhance GABA-stimulated benzodiazepine binding27. We demonstrate here that degeneration of striatonigral fibres increases the density of putative type I benzodiazepine binding sites in the substantia nigra and decreases the density of the putative type II sites. This suggests that type I sites that increase after denervation are postsynaptic, whereas the type II sites reduced by the lesion may be localized to axons or terminals of the striatonigral pathways.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalNature
Volume306
Issue number5938
DOIs
StatePublished - 1983

Fingerprint

Substantia Nigra
Benzodiazepines
Binding Sites
gamma-Aminobutyric Acid
Striatonigral Degeneration
Aminobutyrates
GABA Receptors
Presynaptic Terminals
Denervation
Tissue Distribution
Pharmacology

ASJC Scopus subject areas

  • General

Cite this

Differential localization of type I and type II benzodiazepine binding sites in substantia nigra. / Lo, Mathew M S; Niehoff, Debra L.; Kuhar, Michael J.; Snyder, Solomon H.

In: Nature, Vol. 306, No. 5938, 1983, p. 57-60.

Research output: Contribution to journalArticle

Lo, Mathew M S ; Niehoff, Debra L. ; Kuhar, Michael J. ; Snyder, Solomon H. / Differential localization of type I and type II benzodiazepine binding sites in substantia nigra. In: Nature. 1983 ; Vol. 306, No. 5938. pp. 57-60.
@article{45d3cdc4d48c40b0bd27efca8e04322e,
title = "Differential localization of type I and type II benzodiazepine binding sites in substantia nigra",
abstract = "A number of studies have suggested the existence of multiple benzodiazepine binding sites in the brain1-20. We have recently reported the physical separation of two apparent benzodiazepine binding site subtypes 21, the pharmacological properties, and distribution in tissue sections of which correspond to the putative type I and type II sites 20,22. Benzodiazepine and γ-aminobutyric acid (GABA) receptors have been shown to interact23, and lesions of the GABAergic striatonigral pathway, which lead to GABA supersensitivity24,25, both increase the numbers of GABA binding sites24,26 and enhance GABA-stimulated benzodiazepine binding27. We demonstrate here that degeneration of striatonigral fibres increases the density of putative type I benzodiazepine binding sites in the substantia nigra and decreases the density of the putative type II sites. This suggests that type I sites that increase after denervation are postsynaptic, whereas the type II sites reduced by the lesion may be localized to axons or terminals of the striatonigral pathways.",
author = "Lo, {Mathew M S} and Niehoff, {Debra L.} and Kuhar, {Michael J.} and Snyder, {Solomon H}",
year = "1983",
doi = "10.1038/306057a0",
language = "English (US)",
volume = "306",
pages = "57--60",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "5938",

}

TY - JOUR

T1 - Differential localization of type I and type II benzodiazepine binding sites in substantia nigra

AU - Lo, Mathew M S

AU - Niehoff, Debra L.

AU - Kuhar, Michael J.

AU - Snyder, Solomon H

PY - 1983

Y1 - 1983

N2 - A number of studies have suggested the existence of multiple benzodiazepine binding sites in the brain1-20. We have recently reported the physical separation of two apparent benzodiazepine binding site subtypes 21, the pharmacological properties, and distribution in tissue sections of which correspond to the putative type I and type II sites 20,22. Benzodiazepine and γ-aminobutyric acid (GABA) receptors have been shown to interact23, and lesions of the GABAergic striatonigral pathway, which lead to GABA supersensitivity24,25, both increase the numbers of GABA binding sites24,26 and enhance GABA-stimulated benzodiazepine binding27. We demonstrate here that degeneration of striatonigral fibres increases the density of putative type I benzodiazepine binding sites in the substantia nigra and decreases the density of the putative type II sites. This suggests that type I sites that increase after denervation are postsynaptic, whereas the type II sites reduced by the lesion may be localized to axons or terminals of the striatonigral pathways.

AB - A number of studies have suggested the existence of multiple benzodiazepine binding sites in the brain1-20. We have recently reported the physical separation of two apparent benzodiazepine binding site subtypes 21, the pharmacological properties, and distribution in tissue sections of which correspond to the putative type I and type II sites 20,22. Benzodiazepine and γ-aminobutyric acid (GABA) receptors have been shown to interact23, and lesions of the GABAergic striatonigral pathway, which lead to GABA supersensitivity24,25, both increase the numbers of GABA binding sites24,26 and enhance GABA-stimulated benzodiazepine binding27. We demonstrate here that degeneration of striatonigral fibres increases the density of putative type I benzodiazepine binding sites in the substantia nigra and decreases the density of the putative type II sites. This suggests that type I sites that increase after denervation are postsynaptic, whereas the type II sites reduced by the lesion may be localized to axons or terminals of the striatonigral pathways.

UR - http://www.scopus.com/inward/record.url?scp=0020618970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020618970&partnerID=8YFLogxK

U2 - 10.1038/306057a0

DO - 10.1038/306057a0

M3 - Article

C2 - 6314146

AN - SCOPUS:0020618970

VL - 306

SP - 57

EP - 60

JO - Nature

JF - Nature

SN - 0028-0836

IS - 5938

ER -